Page 15 - Flipbook
P. 15
434 – IMvigor130 study: Exploratory analysis favours atezolizumab over chemotherapy in high PD-L1 cisplatin-ineligible patient population
Galsky MD, et al. Virtual poster presentation at ASCO GU
2021; abstract 434.
